Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that is metastatic (Stage IV) and not amenable to resection with curative intent.
If present, clinically significant or symptomatic amounts of ascites should be drained prior to Day 1.
Have had no prior systemic treatment for metastatic disease. Prior adjuvant or neo-adjuvant chemotherapy or radiochemotherapy (other than nab-paclitaxel) is allowed if completed ≥3 months prior to enrollment and no lingering toxicities are present.
Prior radiation therapy for treatment of cancer is allowed to \<25% of the bone marrow.
Phase 2: archival tumor tissue or be willing to provide a pre-treatment biopsy.
Measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Discontinued all previous treatments for cancer ≥4 weeks prior.
Adequate organ function.
Life expectancy of at least 3 months.
You may not be if
Serious concomitant systemic disorder.
Have received first line treatment for metastatic pancreatic cancer.
Received prior treatment with nab-paclitaxel.
Have known central nervous system malignancy or metastasis.
Current hematologic malignancies.
Participated within the last 30 days in a clinical trial involving an investigational product.
Women with a positive pregnancy test or lactating.
Have endocrine pancreatic tumors or ampullary cancer.
Currently enrolled in another clinical trial.
Have a known additional malignancy that is progressing or required active treatment within the past 1 year.
Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug formulations.
Are taking certain anti-coagulant medications such as warfarin and are unable to be switched to other similar medicines.
Clareo Health | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
